A post-authorization efficacy study to evaluate the long-term efficacy and durability of Ibalizumab (Trogarzo) in combination with other antiretrovirals
Latest Information Update: 20 Oct 2021
At a glance
- Drugs Ibalizumab (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms PROMISE
- 13 Oct 2021 According to a Theratechnologies media release, the enrollment of patients in this study is expected to begin in in the fourth quarter of 2021.
- 04 Mar 2021 New trial record
- 25 Feb 2021 According to a Theratechnologies media release, this study has been requested by EMA in Europe as a post-authorization efficacy study to evaluate the long term efficacy and durability of Trogarzo in combination with other antiretrovirals.